Purpose: We evaluated the outcome of repeat transurethral bladder tumor resection for high risk nonmuscle invasive bladder cancer before induction and maintenance bacillus Calmette-Guerin.
Materials And Methods: Included in the study were 151 consecutive patients with a mean age of 68.6 years (range 32 to 86) with primary high grade, nonmuscle invasive (Ta, T1 or CIS) bladder cancer. All patients underwent repeat transurethral bladder tumor resection and were shown by repeat resection to be tumor-free or have residual tumor before bacillus Calmette-Guerin. The bacillus Calmette-Guerin response was evaluated by disease recurrence and progression.
Results: A total of 70 tumor-free patients and 47 with residual tumor received bacillus Calmette-Guerin induction and maintenance therapy after repeat transurethral bladder tumor resection, of whom 84 (71.8%) were disease-free during followup. In the tumor-free group 11.4% of tumors recurred compared with 27.7% in the residual tumor group (p <0.05). Progression was noted in 5.7% of tumor-free cases vs 17.0% of residual tumor cases (p <0.05). Time to recurrence was significantly less in the residual tumor group than in the tumor-free group (17.8 vs 23.9 months, p <0.001).
Conclusions: Tumor-free status at repeat transurethral bladder tumor resection improves the bacillus Calmette-Guerin response rate and delays tumor recurrence. During followup recurrence in residual tumor-free patients develop more likely as low grade lesions than in patients with residual tumor at repeat transurethral bladder tumor resection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.juro.2010.02.026 | DOI Listing |
Tuberculosis (Edinb)
January 2025
Clinical Research Center, Masan National Tuberculosis Hospital, Changwon, 51755, Republic of Korea. Electronic address:
Tuberculosis (TB) remains a highly lethal infectious disease. The primary preventive measure is Bacille Calmette-Guérin (BCG), a live attenuated vaccine. However, the current intradermal vaccination method with 10-dose vials faces challenges such as inadequate infant injection, inaccurate dispensing, and unstable storage.
View Article and Find Full Text PDFMalays J Med Sci
December 2024
Research Centre for Public Health and Nutrition, Research Organisation for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia.
Southeast Asia (SEA) countries are characterised by a high burden of tuberculosis (TB). This research seeks to compile evidence of the prevalence and risk factors associated with TB among children in SEA countries. The searching of articles was conducted for four databases (PubMed, Scopus, Embase, and the Web of Science) published between 2013 and 2023 in the English language.
View Article and Find Full Text PDFJ Pak Med Assoc
January 2025
Department of Physiology, Karachi University, Karachi, Pakistan.
Bladder cancer remains a significant global health concern, being the 10th most common malignancy worldwide and the 6th most common neoplasia in males, with alarming annual incidence and mortality rates. The current narrative review was planned to delve into the multifaceted landscape of bladder cancer, exploring its epidemiology, risk factors and diagnostic modalities. While white light cystoscopy has long been considered the gold standard for bladder cancer diagnosis and surveillance, the emergence of blue light cystoscopy has ushered in a new era of early detection.
View Article and Find Full Text PDFRev Argent Microbiol
January 2025
Servicio de Microbiología, Universidad Católica de Córdoba, Clínica Universitaria Reina Fabiola, Córdoba, Argentina. Electronic address:
The WHO aims to reduce the number of deaths from TB by 95% and decrease its incidence rate by 90% between 2015 and 2035. The recommended rapid diagnostic tests are accurate and cost-effective, allow for a prompt start to treatment, and influence other outcomes that are important to the patient. To detect latent infection, the tuberculin skin test and interferon γ release (IGRA) tests are used.
View Article and Find Full Text PDFEur Urol
January 2025
2nd Urology Department, Sismanoglion Hospital, National & Kapodistrian University of Athens, Athens, Greece.
For patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for whom bacillus Calmette-Guérin (BCG) treatment has failed, bladder preservation is a high priority. Immune checkpoint inhibitors have shown promise, but systemic administration is associated with substantial toxicity. In this single-arm phase 2 study, 30 patients with NMIBC after BCG failure were treated with intravesical durvalumab every 6 wk.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!